Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

600196 · SSE · China

Public Market Listing

600196SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
PDE5Small molecule
Alzheimer's Disease
Phase 3
BCMA x CD3Multispecific antibody
Multiple Myeloma

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
May 2027 (1)
Velinotamig (GR1803)Phase 2Multiple Myeloma
Est. primary completion 2027-05-12 · NCT06566547 · CT.gov ↗
What to watch
June 2027 (1)
Velinotamig (GR1803)Phase 1/2Systemic Lupus Erthematosus, Auto Immune Disease
Est. primary completion 2027-06-01 · NCT07348055 · CT.gov ↗
What to watch
July 2027 (1)
Velinotamig (GR1803)Phase 2Multiple Myleoma
Est. primary completion 2027-07-01 · NCT06952075 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Velinotamig (GR1803)Phase 1/2Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Est. primary completion 2029-01 · NCT07738822 · CT.gov ↗
What to watch
March 2029 (1)
Velinotamig (GR1803)Phase 3Multiple Myeloma
Est. primary completion 2029-03 · NCT07452198 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

January 2026Filing acceptedVelinotamig (GR1803)China's NMPA accepts the conditional marketing application for velinotamig, with priority review
CN, NMPA · Genrix Bio · Source ↗

Financial reports

No financial reports recorded.